Unmet Clinical Need

​A way to reduce procedural risks and increase effectiveness of the therapy delivery in the central nervous system which enables wider adoption by physicians

Healthcare Landscape

Currently no FDA cleared medical device commercially available for CNS gene therapy delivery to the cisterna magna via lumbar access insertion

Creation of new market for gene therapy delivery and a novel platform technology for additional cerebrospinal fluid procedures

Voice of the Customer

Direct sub-occipital puncture is done using fluoroscopy which is only
1-dimensional; having video camera
ability will create
3-dimensional view for the insertion; it will make procedure safer and less complex.

-Interventional Radiologist at clinical trial company

I wanted to solve the problem of safely delivering CNS gene therapy. The Esperanza catheter system is designed to solve this problem and opens the window for other applications as a new platform technology!”


-Innovator & Interventional Neuroradiologist at hospital

Can also leverage your technology for other product / therapeutic areas in human body with “clear fluids” and “narrow spaces” due to its small size and video camera capability such as urinary system, respiratory system, subarachnoid hemorrhage, etc.

-Neurologist at hospital

Difficult to get trained neurosurgeons to do ICM approach to run clinical trials for gene therapies; not many people trained to do that procedure. So, it will be beneficial to have scalable procedure.
​
-Chief Medical Officer at pharmaceutical company

The safe delivery of gene therapies is of utmost importance, so delivery techniques and
access sites are critical. Having an imaging-guided product that could be utilized for lumbar cistern access for precise gene therapy delivery to the cisterna magna would be ideal.

​-Chief Medical Officer at pharmaceutical company

Disclaimer: Product and related statements are not FDA cleared. The device is currently under development and is not commercially available for sale.